AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06593756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis
Description: Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
Study NCT06593756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Doppler
Description: In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
Study NCT06593756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioreactance
Description: Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
Study NCT06593756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising
Description: Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
Study NCT06593756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vena Cava Ultrasound
Description: Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
Study NCT06593756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory /-inspiratory occlusion test
Description: In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
Study NCT06593756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus
Description: To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning
Study NCT06609577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaphragm Ultrasound-Guided External Diaphragm Pacing
Description: This intervention, Diaphragm Ultrasound-Guided External Diaphragm Pacing (DU-EDP), is distinguished by its personalized approach, where diaphragm pacing is dynamically adjusted based on real-time diaphragm function measurements obtained through bedside diaphragm ultrasound (DU). Unlike standard external diaphragm pacing (EDP) interventions that use uniform pacing parameters, DU-EDP allows for the customization of pacing intensity, frequency, and duration for each patient. This intervention specifically integrates novel diaphragm function indices, such as diaphragm thickening fraction (DTF) and diaphragmatic rapid shallow breathing index (D-RSBI), to enhance precision in weaning from mechanical ventilation. The combination of these advanced metrics with real-time ultrasound guidance makes DU-EDP a highly individualized and innovative intervention for critically ill, mechanically ventilated patients.
Study NCT06591403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the index and middle fingers of each participant&amp;#39;s active hand
Description: A pulse oximeter was placed simultaneously on the index and middle fingers of each participants active hand while they were in an upright sitting position. After the pulse oximeter was placed on both fingers for one minute, stable values seen on its screen for at least three seconds were recorded. Then, the participants were placed in a supine position, and after a 10-minute rest, similar measurements were repeated with a pulse oximeter placed on the index and middle fingers of the active hand.
Study NCT06596681 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GA+clozapine
Description: Patients were first given intracranial injections of GA and observed for 14-28 days, followed by a dose-climbing trial of clozapine medication, and finally, after the investigators had determined an effective dose of clozapine, the patients were given a fixed dose of clozapine orally for three months.
Study NCT06590415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous adipose tissue biopsy
Description: Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.
Study NCT06590415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue biopsy
Description: Under local anesthesia, subcutaneous adipose tissue will be collected from 2 puncture points in the umbilical region for a total volume of 2 mL.
Study NCT06590415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: One 4 mL tube of blood will be collected
Study NCT06590415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: One 4 mL tube of blood will be collected
Study NCT06591338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Study NCT06591338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study NCT06587373 — intervention group
Intervention type: OTHER
Intervention: Assessment of the quality of mother-child dyadic relationships
Description: Filling out questionnaires
Study NCT06112509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular exam
Description: Interrogation, videonystagmoscopy, videonystagmography, video-head-impulse-test
Study NCT06383273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELT-300 sublingual tablet
Description: Each dose of MELT-300 will be provided as a single sublingual tablet, containing 3 mg midazolam and 50 mg ketamine. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Study NCT06383273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midalozam sublingual tablet
Description: Each dose of midazolam will be provided as a single sublingual tablet, containing 3 mg midazolam. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Study NCT06383273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual tablet
Description: Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Study NCT05480748 — intervention group
Intervention type: DEVICE
Intervention: monitoring
Description: ORI warning time, SpO2 warning time, added time were recorded.
Study NCT04938583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
Study NCT04938583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/Kg Day 1 (every 21 days) until progression
Study NCT04938583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
Study NCT04938583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV Day 1 x 6 cycles (every 21 days)
Study NCT04445571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thin catheter technique or standard ET-tube for surfactant administration
Description: Surfactant administration by intubation with regular ET-tube followed by immediate extubation to CPAP (INSURE) or by thin catheter during spontaneous breathing and continued CPAP.
Study NCT04353180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
Description: After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT04353180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment
Description: Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT04353180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin (13 cis retinoic acid ) capsules
Description: 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days
Study NCT04353180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized 13 cis retinoic acid
Description: Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days
Study NCT04353180 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT05047809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jingchuang Ointment(JCO)
Description: Applied once a day on the wounds
Study NCT05047809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular Treatment
Description: Do not use the Jingchuang Ointment(JCO), as the regular treatment as usual.
Study NCT06503172 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Taiwanese whole grain job's tear (red job's tear)
Description: 300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8
Study NCT06503172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Taiwanese whole grain job's tear (red job's tear)
Description: 300cc drink made from red job's tear, 2 bottle/day from week 0 to week 8
Study NCT06503172 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: White job's tear
Description: 300cc drink made from white job's tear, 2 bottle/day from week 0 to week 8
Study NCT05941078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICF-based post-stroke rehabilitation program
Description: Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
Study NCT06539910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
Study NCT06539910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
Study NCT05992922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC265 Ophthalmic Solution 1%
Description: 1 drop will be instilled in each eye twice a day
Study NCT05992922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution (Vehicle)
Description: 1 drop will be instilled in each eye twice a day
Study NCT05447884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A zero impedance mode, controlling a wearable bilateral hip exoskeleton
Description: The bilateral hip exoskeleton has two degrees of freedom to enable the hip joint extension and flexion movement on both left and right sides. The zero impedance mode will not provide any assistance or resistance to the hip joints.
Study NCT04807842 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: vaginal gel
Description: The placebo gel is a non-buffered gel. The active device is an acidic gel.
Study NCT04897828 — intervention group
Intervention type: DEVICE
Intervention: Covered Stent placement
Description: Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
Study NCT05447884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton
Description: The personalized optimal assistance mode includes both individualized hip flexion and hip extension assistance, which is determined by using the reinforcement learning-based automatic control parameters tuning during walking tasks. Therefore, the personalized optimal assistance will be able to improve the walking gait performance and reduce the energetic consumption.
Study NCT05447884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A free walking mode, without wearing a wearable bilateral hip exoskeleton
Description: The free walking mode will not include the usage of the wearable bilateral hip exoskeleton, and the human walking subjects will conduct pure natural walking tasks.
Study NCT04783493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive magnetic stimulation of the spinal cord
Description: Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds
Study NCT04783493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coil will not be connected to the stimulation device
Description: coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated
Study NCT04908566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody combined with FOLFIRINOX regimen
Description: Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。
Study NCT04908566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 antibody combined with SOX program
Description: Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles.
Study NCT05458609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant 10 mg
Description: 10 mg of Lemborexant
Study NCT05458609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of Naltrexone
Study NCT05458609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of Naltrexone
Study NCT04874246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
Study NCT05228522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: 16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
Study NCT05221580 — intervention group
Intervention type: DRUG
Intervention: Ryzodeg®
Description: Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Study NCT04784000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1: AT-527 550 mg
Description: AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1
Study NCT04784000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: carbamazepine
Description: Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25
Study NCT04784000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3: AT-527 550 mg + carbamazepine
Description: AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
Study NCT04784000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3: AT-527 1100 mg + carbamazepine
Description: AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
Study NCT05178407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cube
Description: Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)
Study NCT05178407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control bouillon cube (iodine-only)
Description: Bouillon cube fortified with 30 µg/g Iodine (KIO3)
Study NCT06130735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Computerized Training
Description: Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
Study NCT04637438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: FMT via colonoscopy
Study NCT04637438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water infusion via colonoscopy
Study NCT05052138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile massage
Description: Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
Study NCT06291688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile healthcare education game
Description: Game group will download an APP on a smart phone and play the mobile game which contains the educaitonal content regarding EGFR-related cutaneous adverse drug reactions.
Study NCT06291688 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile healthcare education application
Description: Text group will download an APP on a smart phone and open the APP to see the text regarding EGFR-related cutaneous adverse drug reactions.
Study NCT04790084 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention